Aflac (AFL) Q2 2026 earnings review
Buybacks Mask Stalling Sales and Margin Pressures
Aflac delivered a mixed Q2 2026. While GAAP net earnings jumped 37.7% YoY to $825 million, this was primarily an accounting illusion driven by significantly lower net investment losses compared to the prior year. The core operating engine is decelerating: Adjusted EPS fell 1.7% to $1.75, and total revenues dropped 1.0%. The relentless weakening of the Japanese Yen (down 9.3% YoY) erased Yen-level earnings growth, costing $0.05 per share. More concerningly, the high-flying Japan sales momentum came to a sudden halt, and U.S. margins contracted. A massive $983 million share repurchase program remains the primary floor supporting per-share metrics.
🐂 Bull Case
Management executed $983 million in share repurchases and $309 million in dividends. The aggressive, steady buyback cadence mechanically inflates EPS and provides a strong valuation floor.
Despite top-line stagnation, Aflac Japan's benefit ratio improved by 250 basis points to 64.0%. This drove a 3.4% increase in pretax adjusted earnings on a Yen basis.
🐻 Bear Case
The Yen depreciated 9.3% YoY against the USD (average 159.45 vs 144.60). This severely suppresses Aflac's USD-reported financials, turning a 3.4% local-currency Japan profit gain into a 6.2% USD decline.
Aflac U.S. pretax adjusted earnings fell 4.6% to $370 million, driven by a 220 basis point spike in the benefit ratio to 49.5%. Higher benefits are eating into the segment's modest revenue growth.
⚖️ Verdict: ⚪
Neutral. The company is expertly managing what it can control—share count, Japan underwriting margins, and U.S. persistency. However, severe FX headwinds, stalling Japan sales, and U.S. margin compression make organic growth extremely difficult to achieve.
Key Themes
Japan Sales Momentum Hits a Wall
Management praised their 'successful product initiatives' like Anshin Palette and Miraito in the press release. However, the raw data contradicts the rosy narrative: Aflac Japan's new annualized premium sales reversed violently, falling 5.6% YoY to ¥19.6 billion. This follows a blistering 25.5% growth rate in Q1 2026 and highlights the company's heavy reliance on the initial launch cycles of specific products to drive volume.
U.S. Margins Deteriorating
While Aflac U.S. eked out a 2.3% increase in net earned premiums, the flow-through to the bottom line was poor. Total benefits and claims surged 7.0%, pushing the benefit ratio up 220 basis points to 49.5%. This caused U.S. pretax adjusted earnings to decelerate by 4.6% YoY. The shift toward group voluntary and network dental/vision products is supporting the top line but pressuring overall segment margins.
Yen Depreciation Crushes USD Results
The macro picture remains a heavy anchor. The average exchange rate of 159.45 Yen/USD was 9.3% weaker than the prior year. This translates directly to a $0.05 hit to adjusted EPS. The currency translation turns a resilient local business into a shrinking U.S. reporting segment: Japan's total adjusted revenues dropped 12.6% in USD terms despite only a 3.6% decline in Yen.
Aggressive and Consistent Capital Returns
Aflac is effectively using its fortress balance sheet to manufacture EPS stability. The company repurchased another $983 million in stock in Q2 (following $1.0 billion in Q1) and paid $309 million in dividends. The annualized adjusted return on equity excluding FX remeasurement sits at a very healthy 16.6%, proving the balance sheet mechanics are working flawlessly.
Japan Underwriting Profitability
While sales disappointed, Aflac Japan's underwriting discipline is a massive bright spot. The total benefits and claims ratio improved by 250 basis points YoY to 64.0%. This margin expansion is keeping Yen-based pretax earnings positive (+3.4% YoY) even as top-line premiums contract due to older blocks running off and reinsurance transactions.
U.S. Persistency and Sales Execution
The U.S. segment remains the stabilizing force for the top line. U.S. sales grew 2.6% to $349 million, benefiting from group voluntary benefits and network dental/vision products. More importantly, 12-month rolling persistency ticked up 20 basis points to 79.4%, ensuring that the book of business continues to compound slowly despite weakness in the legacy core agent channel.
Other KPIs
Reversing. Down drastically from a $20 million gain in the prior year. The segment was dragged down by lower adjusted net investment income from reduced short-term income, reduced hedge benefits, and higher interest expense ($62M vs $51M).
Decelerating. Down 4.1% YoY from $42.97. Despite strong operating ROE and share repurchases, the heavy impact of the depreciating Yen and investment portfolio dynamics continue to pressure the core adjusted book value.
Stable to Decelerating. Aflac Japan adjusted net investment income fell 2.9% in Yen (11.9% in USD to $616M) due to reduced call income and lower dollar-denominated floating-rate income. Aflac U.S. adjusted net investment income was effectively flat at $208M (+0.5%).
Key Questions
Japan Sales Trajectory Post-Miraito
With Japan sales dropping 5.6% YoY, how much of this is purely a tough comparison against the Miraito launch, versus underlying fatigue in the distribution channels? What is a normalized run-rate for Japan sales over the next 12-18 months?
U.S. Benefit Ratio Expansion
The U.S. benefit ratio spiked 220 basis points to 49.5%. How much of this was driven by the mix shift towards group and dental/vision products versus underlying claims inflation in the core voluntary business?
Commercial Real Estate (CRE) Exposure Update
Given the lack of details in the press release regarding the credit portfolio, what are the current CECL reserves and impairment levels on the Commercial Real Estate and middle-market loan portfolios this quarter?
Capital Return Sustainability
You continue to repurchase roughly $1 billion in stock per quarter. Is this pace sustainable through the remainder of 2026 without dipping into minimum required holdco liquidity, especially if the Yen remains structurally weak?